{
  "id": 15610563,
  "title": "AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial",
  "url": "https://urgent.news/2026/10/19/abbvies-skyrizi-combo-beats-skyrizi-alone-in-mid-stage-crohns-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T12:51:49.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/abbvies-skyrizi-combo-beats-skyrizi-alone-in-mid-stage-crohns-trial/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is codenamed ABBV-466 and combines Skyrizi, an IL-23 ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}